We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/3/2021 14:11 | Anyone else asked John Palmer via LinkedIn in why he hasn’t added Orange Avenue Technologies LLC to his bio? Where it is based and who else is on the Board of Directors. I suggest you should like me Time to investigate this cloak of secrecy | scottdavid70 | |
09/3/2021 09:46 | Meanwhile in this fantasy scenario you are guaranteed of getting a BONUS and a deferred salary of an extra 2 months equating to £100,000. Let me see if I can imagine this fantasy.... | scottdavid70 | |
09/3/2021 09:45 | Imagine dragging out the RTO so you could get Iclaprim in the position to be sold, as a RTO can be as quick as 4 weeks, and then taking a slice of the new commission you have said is a fair outcome for shareholders? Can you imagine it? Can you? I am seeing if I can imagine it....mmmm | scottdavid70 | |
09/3/2021 09:37 | Interesting to note how Walbrook can’t tell investors anything about the new Company. Wonder where it is situated and who else is on the Board??? Maybe owned by John Palmer but who else is on the Board and gets a piece of the 10% action now??? Why the secrecy of it if it’s all above board? | scottdavid70 | |
08/3/2021 13:07 | Sure when you can explain why Motif have not updated shareholders on anything to do with Iclaprim for around 2 years. They still have a contractual agreement and have basically said there are no pending transactions but have given the asset to the same person who couldn’t sell it already for 18 months. Makes zero sense when there are many other options out there to try an new avenue to sell it and this needs a explanation as to why this has happened and is hard working ordinary shareholders best interests. | scottdavid70 | |
08/3/2021 12:45 | Nor me. Now will you belt up??? | small crow | |
08/3/2021 10:43 | Ok Scott you've convinced me. I won't be putting any more money into Motif stock for the foreseeable future. | bi11y ray va1entine | |
06/3/2021 06:21 | All the dilution you have suffered as shareholders wouldn’t have happened if Iclaprim was sold by the guy who couldn’t sell but NOW supposedly can? Sure I buy that..... | scottdavid70 | |
06/3/2021 06:15 | I will keep saying why do you go to the trouble of creating a new company and hiring the same person who couldn’t sell your asset in the previous 16 months? You wouldn’t do it for your house so why do you NOW believe a different outcome is possible? Doesn’t add up and when something doesn’t add up with Motif it’s very bad news | scottdavid70 | |
06/3/2021 06:11 | As such, the Transaction constitutes a related party transaction in accordance with Rule 13 of the AIM Rules for Companies” This is from Investopedia on related-party transactions and when you consider no one can find Orange Avenue Technologies LLC it makes for uncomfortable reading “ Although related-party transactions are themselves legal, they may create conflicts of interest or lead to other illegal situations. Public companies must disclose these transactions” | scottdavid70 | |
05/3/2021 22:21 | Zero sign still of Orange Avenue Technologies, LLC. Nada Nothing Zero Why the secrecy John? | scottdavid70 | |
05/3/2021 19:28 | LSE showing how easy it’s been for Motif to pull the wool over the shareholders eyes. Embarrassing dialogue. Clueless Glad I have invested a bit of cash for a few people to help me hunt down Orange Avenue Technologies and to dissect the AIM admission document when released for anything we need to know that looks a bit untoward | scottdavid70 | |
05/3/2021 11:53 | Wouldn’t be surprised if Delaware is where our John has set up Orange Avenue Technologies LLC. If you watched the Laudromat with Meryl Streep you will know why. Here is an article on 1209 North Orange Street for those who don’t know: hxxps://www.nytimes. | scottdavid70 | |
05/3/2021 10:35 | billy wins. | small crow | |
05/3/2021 09:23 | You raise a good point there Scott. Why would somebody talk to you if they weren't getting paid to? | bi11y ray va1entine | |
05/3/2021 08:55 | Think I am making perfect sense. I think your probably work for the company | scottdavid70 | |
05/3/2021 08:43 | You're not making much sense Scott. I think you're probably just a troll. | bi11y ray va1entine | |
05/3/2021 08:31 | Ask the NOMAD, Walbrook and Motif to explain how it’s fair value for shareholders to lose another 10% on top of everything else we have lost? How can this drug which Graham said so many times was so valuable be now worth just a dollar to a company none of us can find? There aren’t many antibiotics that just need one phase iii trail as we know. It has good patent protection and 2 new patents recently with Sandoz. Something is not right here in my humble opinion | scottdavid70 | |
05/3/2021 08:29 | No I am saying that a drug that we have had zero updates on despite being told we would I.e Lamellar. A drug that has been in trials with the US Army since 2019 that we have had no updates on. A drug that couldn’t be sold apparently is now worth setting up a company for. If it’s based in Panama et the profits will be tax free and any other Director’s impossible to find out. Why hasn’t John Palmer updated his LinkedIn page as he is advertising the fAct he is selling Iclaprim with the new company? One that that has been consistent with Motif is that if it doesn’t make sense such as HARB trials and EMA submission being cancelled then there is an ulterior motive. The only thing that makes sense here is that there is considerable value in Iclaprim and therefore worth setting up a company for. Corporate Greed has been the common denominator here at the expense of the hard working ordinary investor. I don’t see this as any difference | scottdavid70 | |
05/3/2021 08:13 | Are you saying you think they can ignore the terms of the Iclaprim sale contract simply by basing the company overseas, Scott? | bi11y ray va1entine | |
05/3/2021 06:53 | Make it your goal today to email Motif, Walbrook and the NOMAD to ask about Orange Avenue Technologies, LLC. The size of your future wealth and how you want to live your life depends on it. Ask who else is on the Board and where exactly is it incorporated? Why isn’t Mr Palmer making it visible on his LinkedIn page? Many questions no answers so far | scottdavid70 | |
04/3/2021 23:11 | Dont lose sight of the possible sleight of hand here $1 billion at 10% is $100 million Split 3 ways Oh but we are all focused on the RTO for value.......whilst the major action is happy in Panama with Orange Avenue Technologies LLC Eyes peeled everyone | scottdavid70 | |
04/3/2021 22:50 | Snt and mogp both now spac companies both set to rocket both at ridiculously cheap prices check them out Mogp even renaming as spac uk plc to capitalise on the boom | hasago | |
04/3/2021 22:49 | John Palmer who is on LinkedIn for Tamarack who is selling Iclaprim, who still has the proposal up on his activity, spelling mistakes and all, still doesn’t list Orange Avenue Technologies, LLC as something he owns. However, he is APPARENTLY the only owner and therefore only BENEFICIARY of the extra commission he will now receive...why wouldn’t you be telling everyone?? Where is Orange Avenue Technologies, LLC based Mr Palmer? Who else is on the Board John? Why the secrecy? Is Mr Lumsden or Mr Gold involved in anyway with Orange Avenue Technologies, LLC? Strange when you are now getting a 10% commission for the very thing you couldn’t sell before. Why are you keeping it so quiet John? “2+2=5” Einstein | scottdavid70 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions